Consun Pharmaceutical Group (HKSE:01681) Additional Paid-In Capital : HK$20 Mil(As of Dec. 2023)

View and export this data going back to 2013. Start your Free Trial

What is Consun Pharmaceutical Group Additional Paid-In Capital?

Consun Pharmaceutical Group's quarterly additional paid-in capital increased from Dec. 2022 (HK$0 Mil) to Jun. 2023 (HK$16 Mil) and increased from Jun. 2023 (HK$16 Mil) to Dec. 2023 (HK$20 Mil).

Consun Pharmaceutical Group's annual additional paid-in capital declined from Dec. 2021 (HK$24 Mil) to Dec. 2022 (HK$0 Mil) but then increased from Dec. 2022 (HK$0 Mil) to Dec. 2023 (HK$20 Mil).

Consun Pharmaceutical Group Additional Paid-In Capital Historical Data

The historical data trend for Consun Pharmaceutical Group's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Consun Pharmaceutical Group Additional Paid-In Capital Chart

Consun Pharmaceutical Group Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Additional Paid-In Capital

Get a 7-Day Free Trial

24.23

19.85

Consun Pharmaceutical Group Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Additional Paid-In Capital	Get a 7-Day Free Trial															24.23	-	-	15.69	19.85

Consun Pharmaceutical Group Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Consun Pharmaceutical Group Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Consun Pharmaceutical Group's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Consun Pharmaceutical Group (HKSE:01681) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Consun Pharmaceutical Group Ltd (HKSE:01681) » Definitions » Additional Paid-In Capital

Traded in Other Exchanges

C1P:Germany

Address

71, Dongpeng Avenue, Eastern section, Guangzhou Economic and Technological Development, Guangzhou, CHN

Website

https://www.chinaconsun.com

Consun Pharmaceutical Group Ltd is a biotechnology company with sales operations throughout China. Its principal activities are making and selling pharmaceutical products. The company has two reportable segments: the Consun pharmaceutical segment, which is the key revenue driver, and makes and sells modern Chinese medicines and medical contrast medium, and the Yulin pharmaceutical segment, which manufactures and sells traditional Chinese medicines. Consun derives revenue from kidney medicines, contrast mediums, orthopedics medicines, dermatologic medicines, hepatobiliary medicines, medicines for women and children, and others.

Consun Pharmaceutical Group (HKSE:01681) Headlines

No Headlines